Laura Saracino1, Chandra Bortolotto2, Stefano Tomaselli1, Elia Fraolini1, Matteo Bosio1, Giulia Accordino1, Francesco Agustoni3, David M Abbott4, Emma Pozzi3, Dimitrios Eleftheriou5, Patrizia Morbini6, Pietro Rinaldi7, Cristiano Primiceri7, Andrea Lancia8, Patrizia Comoli9, Andrea R Filippi8, Giulia M Stella10. 1. Department of Medical Sciences and Infective Diseases, Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100, Pavia, Italy. 2. Department of Intensive Medicine, Unit of Radiology, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, Pavia, Italy. 3. Department of Medical Sciences and Infective Diseases, Unit of Oncology, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100, Pavia, Italy. 4. Department of Anesthesia and Intensive Care, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100, Pavia, Italy. 5. Department of Internal Medicine, ASST, Pavia, Italy. 6. Department of Molecular Medicine, Unit of Pathology, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, Pavia, Italy. 7. Department of Intensive Medicine, Unit of Cardiothoracic Surgery, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, Pavia, Italy. 8. Department of Medical Sciences and Infective Diseases, Unit of Radiation Therapy, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, Pavia, Italy. 9. Cell Factory and Pediatric Hematology-Oncology Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. 10. Department of Medical Sciences and Infective Diseases, Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100, Pavia, Italy. g.stella@smatteo.pv.it.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural layers. MPM has a strong association with asbestos, mainly caused by exposure to its biopersistent fibers in at least 80% of cases. Individuals with a chronic exposure to asbestos might develop disease with a 20-40-year latency with few or no symptoms. Such has been the case in the Italian regions of Piedmont and Lombardy, where industrial production of materials laden with asbestos, mainly cements, has been responsible for the onset of a large epidemic. Since 2018, a multidisciplinary team at San Matteo hospital in Pavia has been collecting data on over 100 patients with MPM. The main goal of this project is to define and describe an integrated profile for each MPM case at diagnosis by using data mining and partition analysis. METHODS: Here we bring together exhaustive epidemiologic, histologic and radiologic data of 88 MPM patients that came to our observation and draw correlations with predictive and prognostic significance. RESULTS: The median overall survival (OS) was 15.6 months. Most patients presented with pleural effusion, irrespective of disease stage. Quite unexpectedly, no statistically significant association was demonstrated between OS and TNM disease stage at diagnosis. Although average OS is similar in male and female patients, partition analysis of data underlined a significant differential hierarchy of predictor categories based on patient gender. In females with no smoking history, full chemotherapeutic regimens are associated with better outcomes. Moreover, concerning second line treatments, vinorelbine emerged as the most advantageous choice for female patients, whereas in the male subgroup no statistically significant difference resulted between gemcitabine and vinorelbine. CONCLUSION: A multidisciplinary approach to MPM is mandatory to define better therapeutic approaches, personalize the management and improve patient outcomes.
BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural layers. MPM has a strong association with asbestos, mainly caused by exposure to its biopersistent fibers in at least 80% of cases. Individuals with a chronic exposure to asbestos might develop disease with a 20-40-year latency with few or no symptoms. Such has been the case in the Italian regions of Piedmont and Lombardy, where industrial production of materials laden with asbestos, mainly cements, has been responsible for the onset of a large epidemic. Since 2018, a multidisciplinary team at San Matteo hospital in Pavia has been collecting data on over 100 patients with MPM. The main goal of this project is to define and describe an integrated profile for each MPM case at diagnosis by using data mining and partition analysis. METHODS: Here we bring together exhaustive epidemiologic, histologic and radiologic data of 88 MPM patients that came to our observation and draw correlations with predictive and prognostic significance. RESULTS: The median overall survival (OS) was 15.6 months. Most patients presented with pleural effusion, irrespective of disease stage. Quite unexpectedly, no statistically significant association was demonstrated between OS and TNM disease stage at diagnosis. Although average OS is similar in male and female patients, partition analysis of data underlined a significant differential hierarchy of predictor categories based on patient gender. In females with no smoking history, full chemotherapeutic regimens are associated with better outcomes. Moreover, concerning second line treatments, vinorelbine emerged as the most advantageous choice for female patients, whereas in the male subgroup no statistically significant difference resulted between gemcitabine and vinorelbine. CONCLUSION: A multidisciplinary approach to MPM is mandatory to define better therapeutic approaches, personalize the management and improve patient outcomes.
Entities:
Keywords:
Asbestos; Imaging; Mesothelioma; Multidisciplinary team
Authors: Vanya Delgermaa; Ken Takahashi; Eun-Kee Park; Giang Vinh Le; Toshiyuki Hara; Tom Sorahan Journal: Bull World Health Organ Date: 2011-06-13 Impact factor: 9.408
Authors: Dario Consonni; Sara De Matteis; Barbara Dallari; Angela C Pesatori; Luciano Riboldi; Carolina Mensi Journal: Environ Res Date: 2019-11-29 Impact factor: 6.498
Authors: Jordi Remon; Francesco Passiglia; Myung-Ju Ahn; Fabrice Barlesi; Patrick M Forde; Edward B Garon; Scott Gettinger; Sarah B Goldberg; Roy S Herbst; Leora Horn; Kaoru Kubota; Shun Lu; Laura Mezquita; Luis Paz-Ares; Sanjay Popat; Kurt A Schalper; Ferdinandos Skoulidis; Martin Reck; Alex A Adjei; Giorgio V Scagliotti Journal: J Thorac Oncol Date: 2020-03-14 Impact factor: 15.609
Authors: Francesco Falanga; Pietro Rinaldi; Cristiano Primiceri; Chandra Bortolotto; Olga Oneta; Francesco Agustoni; Patrizia Morbini; Laura Saracino; Dimitrios Eleftheriou; Federico Sottotetti; Giulia Maria Stella Journal: Thorac Cancer Date: 2022-09-02 Impact factor: 3.223